Medicinova Inc (MNOV)
MediciNova is a biopharmaceutical company. Co. is focusing its development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction and prevention of acute respiratory distress syndrome, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. Co.'s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
| Company Name: |
Medicinova Inc |
| Website: |
www.medicinova.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding MNOV: |
2 |
| Total Market Value Held by ETFs: |
$979607 |
| Total Market Capitalization: |
$69.00M |
| % of Market Cap. Held by ETFs: |
1.42% |
|
|
April 23, 2024 • 7:10 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free MNOV Email Alerts:
